Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Licensing: pros and cons for biotech.

Drug discovery today·2009
Same author

Getting real about valuations in biotech.

Nature biotechnology·2005
Same author

Real options are neither complicated nor unrealistic.

Drug discovery today·2004
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Capillary Electrophoresis Separation of Monoclonal Antibody Isoforms Using a Neutral Capillary
14:53

Capillary Electrophoresis Separation of Monoclonal Antibody Isoforms Using a Neutral Capillary

Published on: January 16, 2017

Dissecting monoclonal antibody mega-deals.

Ralph Villiger1, Boris Bogdan

  • 1Avance, Basel GMbH, Basel, Switzerland. ralph.villiger@avance.ch

Mabs
|January 12, 2010
PubMed
Summary

Recent monoclonal antibody (mAb) deals are reaching unprecedented values, even at preclinical stages. Sophisticated deal terms and licensee strategies are driving these significant increases in deal size and structure.

Area of Science:

  • Biotechnology
  • Pharmaceutical industry
  • Drug development

Background:

  • Monoclonal antibody (mAb) deals have recently achieved significant financial milestones.
  • Historically, deals exceeding US$1 billion in milestones were rare.
  • Even early-stage agreements now command substantial valuations.

Purpose of the Study:

  • To analyze the structural components of high-value monoclonal antibody deals.
  • To examine the influence of evolving and complex deal terms.
  • To investigate licensee strategies and their effect on deal size and structure.

Main Methods:

  • Analysis of recent high-value monoclonal antibody deal structures.
  • Examination of financial terms, including co-promotion and profit-sharing clauses.

More Related Videos

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

Related Experiment Videos

Last Updated: Jun 17, 2026

Capillary Electrophoresis Separation of Monoclonal Antibody Isoforms Using a Neutral Capillary
14:53

Capillary Electrophoresis Separation of Monoclonal Antibody Isoforms Using a Neutral Capillary

Published on: January 16, 2017

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

  • Review of licensee strategies and their correlation with deal outcomes.

    • Main Results:

    • Preclinical monoclonal antibody agreements are now reaching valuations previously seen only in late-stage deals.
    • Increasingly sophisticated contractual clauses are becoming standard in high-value transactions.
    • Licensee strategies significantly impact the size and structural complexity of these deals.

    Conclusions:

    • The landscape of monoclonal antibody deal-making has fundamentally shifted towards higher valuations and complex terms.
    • Understanding sophisticated deal structures and licensee strategies is crucial for maximizing value in biopharmaceutical partnerships.
    • The trend indicates a maturing market for monoclonal antibodies, with significant investment even in early development stages.